clinical trial · NCT05043688
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Zhigang Li·phase3·recruiting·n = 426
Resectable Esophageal Squamous Cell CarcinomaCamrelizumabradiotherapy
brief summary
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.
started
Sep 1, 2021
primary completion
Dec 31, 2028
completion
Dec 31, 2030
last updated
Oct 17, 2024
detailed description
This study aimed to evaluate the efficacy and safety of adding immunotherapy to neoadjuvant chemotherapy (CT) or chemoradiotherapy (CRT) compared to neoadjuvant CRT alone for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
official title
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Alone for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NICE 2): a Multi-center, Randomized Phase II Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol